Back to Search Start Over

Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1

Authors :
Restuadi, R
Steyn, FJ
Kabashi, E
Ngo, ST
Cheng, F-F
Nabais, MF
Thompson, MJ
Qi, T
Wu, Y
Henders, AK
Wallace, L
Bye, CR
Turner, BJ
Ziser, L
Mathers, S
McCombe, PA
Needham, M
Schultz, D
Kiernan, MC
van Rheenen, W
van den Berg, LH
Veldink, JH
Ophoff, R
Gusev, A
Zaitlen, N
McRae, AF
Henderson, RD
Wray, NR
Giacomotto, J
Garton, FC
Restuadi, R
Steyn, FJ
Kabashi, E
Ngo, ST
Cheng, F-F
Nabais, MF
Thompson, MJ
Qi, T
Wu, Y
Henders, AK
Wallace, L
Bye, CR
Turner, BJ
Ziser, L
Mathers, S
McCombe, PA
Needham, M
Schultz, D
Kiernan, MC
van Rheenen, W
van den Berg, LH
Veldink, JH
Ophoff, R
Gusev, A
Zaitlen, N
McRae, AF
Henderson, RD
Wray, NR
Giacomotto, J
Garton, FC
Publication Year :
2022

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a complex, late-onset, neurodegenerative disease with a genetic contribution to disease liability. Genome-wide association studies (GWAS) have identified ten risk loci to date, including the TNIP1/GPX3 locus on chromosome five. Given association analysis data alone cannot determine the most plausible risk gene for this locus, we undertook a comprehensive suite of in silico, in vivo and in vitro studies to address this. METHODS: The Functional Mapping and Annotation (FUMA) pipeline and five tools (conditional and joint analysis (GCTA-COJO), Stratified Linkage Disequilibrium Score Regression (S-LDSC), Polygenic Priority Scoring (PoPS), Summary-based Mendelian Randomisation (SMR-HEIDI) and transcriptome-wide association study (TWAS) analyses) were used to perform bioinformatic integration of GWAS data (Ncases = 20,806, Ncontrols = 59,804) with 'omics reference datasets including the blood (eQTLgen consortium N = 31,684) and brain (N = 2581). This was followed up by specific expression studies in ALS case-control cohorts (microarray Ntotal = 942, protein Ntotal = 300) and gene knockdown (KD) studies of human neuronal iPSC cells and zebrafish-morpholinos (MO). RESULTS: SMR analyses implicated both TNIP1 and GPX3 (p < 1.15 × 10-6), but there was no simple SNP/expression relationship. Integrating multiple datasets using PoPS supported GPX3 but not TNIP1. In vivo expression analyses from blood in ALS cases identified that lower GPX3 expression correlated with a more progressed disease (ALS functional rating score, p = 5.5 × 10-3, adjusted R2 = 0.042, Beffect = 27.4 ± 13.3 ng/ml/ALSFRS unit) with microarray and protein data suggesting lower expression with risk allele (recessive model p = 0.06, p = 0.02 respectively). Validation in vivo indicated gpx3 KD caused significant motor deficits in zebrafish-MO (mean difference vs. control ± 95% CI, vs. control, swim distance = 112 ± 28 mm, time = 1.29 ± 0.59 s, speed = 32.0 ± 2.53

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1340015055
Document Type :
Electronic Resource